REBIScan


Overview

REBIScan is building transformative technology that accurately and instantaneously detects vision disorders for timely referral and treatment. The first device, the Pediatric Vision Scanner (PVS), detects amblyopia, the leading cause of vision loss in children. A 3-second scan performed by a non-clinician using the PVS replaces the 5-10 minute clinician examination currently required to detect disease, and it does so with unprecedented accuracy.

Management Team

Chief Executive Officer

Justin G. Shaka

Mr. Shaka is cofounder and CEO of REBIScan. Prior to forming REBIScan, he spent over three years working alongside fellow cofounder Dr. David Hunter at Boston Children's Hospital. Mr. Shaka is considered a leading business expert in the field of vision screening. He received his MBA from Carnegie Mellon's Tepper School of Business, and was named the Entrepreneur of the Year by the University in 2011.

Chairman of the Board

David G. Hunter

Dr. Hunter is co-inventor of the technology behind REBIScan. He currently serves as Professor and Vice-Chair of Ophthalmology at Harvard Medical School, and is Chief of Ophthalmology at Boston Children’s Hospital. He is recognized as a leading expert in amblyopia and other eye conditions affecting children. In 2012 Dr. Hunter was named by the Boston Globe as one of the top 12 innovators in the state of Massachusetts for his work on REBIScan.

Board Director

Steven J. Fleck

Mr. Fleck is cofounder and CEO of Proximedics, and was cofounder and Chief Technology Officer of ClearCount, a medical device firm specializing in RFID technology. He previously worked for Boehringer Laboratories in product development where he was responsible for new products from conception to commercial release. Mr. Fleck has an MBA from Carnegie Mellon University and a degree in Applied Physics and Bioengineering from Cornell University.

Justin Shaka